Unity Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UNBX research report →
About the company
Unity Biotechnology, Inc. functions as a biotechnology enterprise dedicated to creating innovative treatments aimed at slowing down, stopping, or even reversing illnesses associated with the aging process. A core component of their therapeutic development involves senolytic compounds, specifically designed to address various ocular (eye) and neurological conditions.
- CEO
- Craig R. Jalbert
- IPO
- 2018
- Employees
- 16
- HQ
- San Francisco, CA, US
Price Chart
- Market Cap
- $965.60K
- P/E
- -0.13
- P/S
- 0.00
- P/B
- 0.52
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -148.97%
- ROIC
- -96.71%
- 52W High
- $3.10
- 52W Low
- $0.05
- 50D MA
- $0.07
- 200D MA
- $0.85
- Beta
- 1.19
- Avg Volume
- 81.34K
Get TickerSpark's AI analysis on UNBX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our UNBX coverage
Recent articles, reports, and earnings notes.
No research on UNBX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UNBX report →Similar companies
Peers in the same neighborhood.